---
schema_version: "secwatch.filing_event.v1"
accession: "0001437402-26-000012"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:42:01.815847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher

## Summary
- IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
- XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.
- Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).
- Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.
- Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027.

## SEC filing metadata
- accession: 0001437402-26-000012
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/0001437402-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000143740226000012/ardx-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437402-26-000012
- JSON: https://secwatch.observer/filing/0001437402-26-000012.json
- Plain text: https://secwatch.observer/filing/0001437402-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.